Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Study sponsor: Kazia Therapeutics Limited
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-03-30Actual
Enrollment · participants30Actual
Source updated2025-03-24Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.